Online inquiry

IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6853MR)

This product GTTS-WQ6853MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets KLKB1 gene. The antibody can be applied in Hereditary Angioedema (HAE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000892.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3818
UniProt ID P03952
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6853MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11678MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ752MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ6620MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ3468MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BA1126
GTTS-WQ8387MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ9644MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ3258MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ10115MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LAG-525
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW